Matches in SemOpenAlex for { <https://semopenalex.org/work/W2752688736> ?p ?o ?g. }
- W2752688736 endingPage "72" @default.
- W2752688736 startingPage "68" @default.
- W2752688736 abstract "Abstract Background Facial psoriasis was reported in 17–68% of patients with psoriasis and shown to have a negative impact on patients’ personal and health‐related quality of life ( HRQ oL). Objectives To explore the association of facial psoriasis with patients’ HRQ oL and to assess the relationship between ixekizumab ( IXE ) and improvement in facial psoriasis and changes in HRQ oL. Methods This work reports the combined results of two phase III multicentre, randomized, double‐blind, placebo‐controlled, active‐comparator trials in patients with moderate‐to‐severe psoriasis. Patients received placebo, etanercept ( ETN ; 50 mg twice weekly) or IXE [80 mg every 4 weeks (Q4W) or every 2 weeks (Q2W)] for up to 12 weeks following an initial 160‐mg dose. HRQ oL parameters were analysed based on facial psoriasis status at baseline using analysis of covariance models. Improvement was assessed as percentage of patients with no facial psoriasis. Results The combined database included 1133 patients with facial psoriasis and 1437 without. Patients treated with IXE whose facial psoriasis cleared had improved Dermatology Life Quality Index 0.1 responses ( P < 0.01) compared with patients with facial psoriasis at Week 12. At Week 12, clearance of facial psoriasis compared with the presence of facial psoriasis was independently associated with significantly better improvement in Psoriasis Skin Appearance Bothersomeness scores in the IXE Q2W treatment group ( P < 0.01). At Week 12, facial clearance and overall Psoriasis Area Severity Index ( PASI ) improvement were observed in significant numbers of patients treated with IXE compared with ETN and placebo. Facial psoriasis clearance at Week 12 in patients treated with IXE or ETN was positively associated with PASI 75 and PASI 90 achievement. Conclusion Facial psoriasis had a larger negative impact on HRQ oL than no facial psoriasis. Facial psoriasis clearance was associated with improved HRQ oL. Significantly more IXE ‐treated patients had rapid facial clearance vs. ETN and PBO , which led to better clinical outcomes." @default.
- W2752688736 created "2017-09-15" @default.
- W2752688736 creator A5001431413 @default.
- W2752688736 creator A5020129995 @default.
- W2752688736 creator A5034369585 @default.
- W2752688736 creator A5035081726 @default.
- W2752688736 creator A5063280552 @default.
- W2752688736 creator A5069977428 @default.
- W2752688736 creator A5072327100 @default.
- W2752688736 creator A5073211785 @default.
- W2752688736 creator A5080223253 @default.
- W2752688736 date "2017-10-06" @default.
- W2752688736 modified "2023-09-27" @default.
- W2752688736 title "Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials" @default.
- W2752688736 cites W1834455687 @default.
- W2752688736 cites W1988914585 @default.
- W2752688736 cites W2024249616 @default.
- W2752688736 cites W2025869037 @default.
- W2752688736 cites W2029794191 @default.
- W2752688736 cites W2035175785 @default.
- W2752688736 cites W2052898192 @default.
- W2752688736 cites W2056367471 @default.
- W2752688736 cites W2073037264 @default.
- W2752688736 cites W2073972325 @default.
- W2752688736 cites W2087371579 @default.
- W2752688736 cites W2171889601 @default.
- W2752688736 cites W2316726698 @default.
- W2752688736 cites W2418506270 @default.
- W2752688736 cites W2595206558 @default.
- W2752688736 cites W2606263675 @default.
- W2752688736 cites W4239041866 @default.
- W2752688736 cites W4241129348 @default.
- W2752688736 cites W4241432765 @default.
- W2752688736 doi "https://doi.org/10.1111/jdv.14581" @default.
- W2752688736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28881462" @default.
- W2752688736 hasPublicationYear "2017" @default.
- W2752688736 type Work @default.
- W2752688736 sameAs 2752688736 @default.
- W2752688736 citedByCount "19" @default.
- W2752688736 countsByYear W27526887362018 @default.
- W2752688736 countsByYear W27526887362019 @default.
- W2752688736 countsByYear W27526887362020 @default.
- W2752688736 countsByYear W27526887362021 @default.
- W2752688736 countsByYear W27526887362022 @default.
- W2752688736 countsByYear W27526887362023 @default.
- W2752688736 crossrefType "journal-article" @default.
- W2752688736 hasAuthorship W2752688736A5001431413 @default.
- W2752688736 hasAuthorship W2752688736A5020129995 @default.
- W2752688736 hasAuthorship W2752688736A5034369585 @default.
- W2752688736 hasAuthorship W2752688736A5035081726 @default.
- W2752688736 hasAuthorship W2752688736A5063280552 @default.
- W2752688736 hasAuthorship W2752688736A5069977428 @default.
- W2752688736 hasAuthorship W2752688736A5072327100 @default.
- W2752688736 hasAuthorship W2752688736A5073211785 @default.
- W2752688736 hasAuthorship W2752688736A5080223253 @default.
- W2752688736 hasConcept C126322002 @default.
- W2752688736 hasConcept C142724271 @default.
- W2752688736 hasConcept C159110408 @default.
- W2752688736 hasConcept C16005928 @default.
- W2752688736 hasConcept C204787440 @default.
- W2752688736 hasConcept C27081682 @default.
- W2752688736 hasConcept C2776173921 @default.
- W2752688736 hasConcept C2776260265 @default.
- W2752688736 hasConcept C2777011040 @default.
- W2752688736 hasConcept C2779745271 @default.
- W2752688736 hasConcept C2779786854 @default.
- W2752688736 hasConcept C2779951463 @default.
- W2752688736 hasConcept C2780564577 @default.
- W2752688736 hasConcept C71924100 @default.
- W2752688736 hasConceptScore W2752688736C126322002 @default.
- W2752688736 hasConceptScore W2752688736C142724271 @default.
- W2752688736 hasConceptScore W2752688736C159110408 @default.
- W2752688736 hasConceptScore W2752688736C16005928 @default.
- W2752688736 hasConceptScore W2752688736C204787440 @default.
- W2752688736 hasConceptScore W2752688736C27081682 @default.
- W2752688736 hasConceptScore W2752688736C2776173921 @default.
- W2752688736 hasConceptScore W2752688736C2776260265 @default.
- W2752688736 hasConceptScore W2752688736C2777011040 @default.
- W2752688736 hasConceptScore W2752688736C2779745271 @default.
- W2752688736 hasConceptScore W2752688736C2779786854 @default.
- W2752688736 hasConceptScore W2752688736C2779951463 @default.
- W2752688736 hasConceptScore W2752688736C2780564577 @default.
- W2752688736 hasConceptScore W2752688736C71924100 @default.
- W2752688736 hasFunder F4320307758 @default.
- W2752688736 hasIssue "1" @default.
- W2752688736 hasLocation W27526887361 @default.
- W2752688736 hasLocation W27526887362 @default.
- W2752688736 hasOpenAccess W2752688736 @default.
- W2752688736 hasPrimaryLocation W27526887361 @default.
- W2752688736 hasRelatedWork W1978428707 @default.
- W2752688736 hasRelatedWork W2126375175 @default.
- W2752688736 hasRelatedWork W2461170543 @default.
- W2752688736 hasRelatedWork W2462324581 @default.
- W2752688736 hasRelatedWork W2998923669 @default.
- W2752688736 hasRelatedWork W3084613618 @default.
- W2752688736 hasRelatedWork W4245009736 @default.
- W2752688736 hasRelatedWork W4247679967 @default.
- W2752688736 hasRelatedWork W4321997075 @default.